about
Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance.Matrix Metalloproteinase 9 Facilitates West Nile Virus Entry into the BrainQuantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users.Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors.HIV pharmacology: barriers to the eradication of HIV from the CNS.Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques.The role of dietary antioxidant insufficiency on the permeability of the blood-brain barrier.Current understanding of HIV-associated neurocognitive disorders pathogenesis.Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIV-associated encephalopathy.Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemNeuroimmune pharmacology of neurodegenerative and mental diseases.The blood-brain barrier: an engineering perspective.Computational and Pharmacological Target of Neurovascular Unit for Drug Design and Delivery.Toll-Like Receptor-3 Mediates HIV-1-Induced Interleukin-6 Expression in the Human Brain Endothelium via TAK1 and JNK Pathways: Implications for Viral Neuropathogenesis.Impact of current antiretroviral therapies on neuroAIDS
P2860
Q25256746-F42AA638-DE91-40A8-9C4D-D9C73497DBB9Q27486919-89F69180-11C0-4114-A237-6E786E8010A4Q33571865-98733EAF-95F5-40F0-8F48-5B410BDFA342Q33831555-8BF1C739-F3F9-4DAD-A90B-2A250E660CB2Q35879027-46964AEC-661A-4D5F-B532-413A1821B9B9Q36458373-6AF7419D-33C9-41CA-BD3B-F5555B788A08Q36552753-895E7D67-2168-49B3-ACFE-6BB70B8D248CQ36681392-3AE4CBBB-0061-44C8-8CE0-15FA97F04C9EQ36898119-2F8452E4-1775-440C-9AB9-28024F671BE2Q36932005-0FC943EF-1390-4CC1-8D45-1E5CD89798FAQ37310114-2D5359BB-6D47-4FF9-BACF-EF75124E1926Q37395149-BF7AAA23-874B-48F5-A3E5-EB722151EAB2Q37698620-6E0F0180-3C9E-4D8D-BBB6-EC2027E64566Q37785813-5BC479D8-3508-4E40-BC27-8391BA08E183Q38134725-D18A951A-0836-4C6D-805C-28D312081DF6Q41886870-CEF4B927-2637-4D03-8DF3-10360DFEACCBQ47575333-FAE8E64A-5B9B-4C49-B226-C347FF166369Q57831860-72F78489-D26D-4CF1-B33F-EBD9DCEE771C
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The blood brain barrier in HIV infection.
@ast
The blood brain barrier in HIV infection.
@en
type
label
The blood brain barrier in HIV infection.
@ast
The blood brain barrier in HIV infection.
@en
prefLabel
The blood brain barrier in HIV infection.
@ast
The blood brain barrier in HIV infection.
@en
P356
P1476
The blood brain barrier in HIV infection.
@en
P2093
Joseph R Berger
Malcolm Avison
P304
P356
10.2741/1427
P577
2004-09-01T00:00:00Z